SCHEMBL499435

SCHEMBL499435

CN(CCC(OCC#N)c1cccc(Cl)c1)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 2/20 0.39
AOC3 Q16853 1/20 0.37
IDO1 P14902 1/20 0.35
CTSS P25774 3/20 0.34
CTSK P43235 2/20 0.34
RIPK1 Q13546 1/20 0.33
GPR88 Q9GZN0 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP2B6 P20813 1/20 0.33
CTSB P07858 2/20 0.32
PDK2 Q15119 1/20 0.32
AURKA O14965 1/20 0.32
RPS6KB1 P23443 1/20 0.32
UTS2R Q9UKP6 1/20 0.32
AHCY P23526 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CCNE2 O96020 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4755369 0.86 AOC3 (0.41) AOC3IDO1ALDH1A1HTTRAB9A
SCHEMBL499224 0.84 AOC3 (0.40) AOC3IDO1RIPK1GPR88PDK2
SCHEMBL10253790 0.84 AOC3 (0.37) CTSLAOC3IDO1RIPK1GPR88
SCHEMBL31462722 0.81 AOC3 (0.39) AOC3IDO1RIPK1GPR88PDK2
SCHEMBL499264 0.81 REN (0.39) CTSLAOC3IDO1GPR88HTT
SCHEMBL498921 0.81 REN (0.39) CTSLAOC3IDO1GPR88HTT
SCHEMBL499535 0.80 RIPK1 (0.38) AOC3IDO1RIPK1
SCHEMBL4754043 0.77 SLC6A4 (0.40) AOC3IDO1GPR88HTTSMN1; SMN2
SCHEMBL25107446 0.74 KDM4E (0.39) CTSLAOC3RIPK1CYP2B6PDK2
SCHEMBL31332748 0.73 AOC3 (0.42) AOC3IDO1CTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106221-B2 Renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-20100144825-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144825-A1 Renin Inhibitors ACE, REN, DNPEP CTSL 46/4885AOC3 2000/4885IDO1 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.